Generic Azilect Availability
Azilect is a brand name of rasagiline, approved by the FDA in the following formulation(s):
AZILECT (rasagiline mesylate - tablet; oral)
Has a generic version of Azilect been approved?
No. There is currently no therapeutically equivalent version of Azilect available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Azilect. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
Patent 5,453,446
Issued: September 26, 1995
Inventor(s): Youdim; Moussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim
Assignee(s): Teva Pharmaceutical Industries, Ltd. Technion Research and Development Foundation Ltd.
R(+)-N-p-opargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.Patent expiration dates:- February 7, 2017✓
- February 7, 2017
-
R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
Patent 5,532,415
Issued: July 2, 1996
Inventor(s): Youdim; Moussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim & Veinberg; Alex
Assignee(s): Teva Pharmaceutical Industries Ltd. Technion Research and Development Foundation Ltd.
The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.Patent expiration dates:- July 2, 2013✓
- July 2, 2013
-
Stable compositions containing N-propargyl-1-aminoindan
Patent 6,126,968
Issued: October 3, 2000
Inventor(s): Peskin; Tirtsah Berger & Caciularu; Fanny
Assignee(s): Teva Pharmaceutical Industries, Ltd.
A pharmaceutical composition comprising as active ingredient a racemic, S(-), and R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, and at least 60% by weight of at least one pentahydric or hexahydric alcohol. Optionally the composition may contain citric acid and magnesium stearate.Patent expiration dates:- September 18, 2016✓
- September 18, 2016
-
Rasagiline formulations and processes for their preparation
Patent 7,572,834
Issued: August 11, 2009
Inventor(s): Sterling; Jeffrey & Lerner; David & Rosen; Harel & Bronov; Leonid & Medini-Green; Dalia & Iosefzon; Berta & Berger-Peskin; Tirtsah & Lidor-Hadas; Ramy & Bahar; Eliezer
Assignee(s): Teva Pharmaceutical Industries, Ltd.
The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.Patent expiration dates:- December 5, 2026✓
- December 5, 2026
-
Rasagiline formulations of improved content uniformity
Patent 7,815,942
Issued: October 19, 2010
Inventor(s): Peskin; Tirtza Berger
Assignee(s): Teva Pharmaceutical Industries, Ltd.
Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.Patent expiration dates:- August 27, 2027✓✓✓
- August 27, 2027
See also...
- Azilect Consumer Information (Drugs.com)
- Azilect Consumer Information (Wolters Kluwer)
- Azilect Consumer Information (Cerner Multum)
- Azilect Advanced Consumer Information (Micromedex)
- Azilect AHFS DI Monographs (ASHP)
- Rasagiline Consumer Information (Wolters Kluwer)
- Rasagiline Consumer Information (Cerner Multum)
- Rasagiline Advanced Consumer Information (Micromedex)
- Rasagiline Mesylate AHFS DI Monographs (ASHP)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
